Aeterna Zentaris GmbH

General information
Aeterna Zentaris GmbH
Weismüllerstrasse 50
60314 Frankfurt, Hessen

Contact person: Klaus Paulini, Chief Executive Officer, President
Company main phone: +49 (69) 426023228
Company main fax:  +49 (69) 426023444
Year founded:2002
Source of foundation:Subsidiary
Name of foundation source:Aeterna Zentaris, Inc.
Corporate description / mission:
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Aeterna Zentaris is dedicated to the development of therapeutic assets across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).
State of ownership: Subsidiary
Headquarters: HQ: No
  • Biotechnology - Therapeutics and Diagnostics
  • Peptides
  • Small molecules
Primary therapeutic areas:
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
Business model:
  • R&D
  • Subsidiary
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Description of products: